COPD drugs linked to urinary problems in men, study finds

Share this article:

A specific class of drugs used to treat chronic obstructive pulmonary disease may result in urinary problems for patients, new research finds.

The medications are in a drug class called inhaled anticholinergics. That includes treatments such as Spiriva (tiotropium), Atrovent (ipratropium bromide) and Combivent (ipratropium combined with albuterol).

Canadian researchers analyzed the medical records of 565,000 COPD patients aged 66 and older. Of these patients, 9,432 men and 1,806 women developed an inability to pass urine. Among male patients who were taking inhaled anticholinergics, the odds of developing the urinary condition were about 40% higher in those who'd been using the drugs for four weeks or less. They were 80% higher among those with enlarged prostate glands.

"Physicians should highlight for patients the possible connection between urinary symptoms and inhaled respiratory medication use to ensure that changes in urinary flow (i.e., incomplete voiding, urinary incontinence and decreased urinary flow) are reported to the physician," the authors wrote.

The study was published Monday's issue of the Archives of Internal Medicine. The study was conducted at St. Michael's Hospital in Toronto.

Share this article:

More in News

RACs collected nearly $2 million from skilled nursing facilities last year, report ...

Recovery Audit Contractors recovered $1.8 million in Medicare overpayments made to skilled nursing facilities in fiscal year 2013, according to a Congressional report released Monday.

OK nursing home worker threatened to behead colleague in a terrorist act, ...

Police in Oklahoma City have arrested a nursing home worker who allegedly threatened to behead another staff member out of solidarity with the Islamic State in Iraq and Syria, according to news sources.

Jewish Home Lifecare named Innovator of the Year

Jewish Home Lifecare named Innovator of the Year

Jewish Home Lifecare won the top award in the Innovator of the Year category in the third annual McKnight's Excellence in Technology Awards competition.